Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

【24h】

Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

机译：受体状态（ER，PR和HER2）接受Neoadjuvant化疗（BC）后的受体状态（ER，PR和HER2）的临床上显着变化预测预后和指导选择最佳佐剂治疗的选择：应强制性地位的重新调整

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：受体状态（ER，PR和HER2）接受Neoadjuvant化疗（BC）后的受体状态（ER，PR和HER2）的临床上显着变化预测预后和指导选择最佳佐剂治疗的选择：应强制性地位的重新调整
2. O-29 Can ER/PR and HER2 receptor status predict complete pathological response after neo-adjuvant chemotherapy in patients with breast cancer? [J] . T. Sircar, H. Brown, R. Athwal, European Journal of Cancer Supplements . 2010,第6期

机译：O-29 ER / PR和HER2受体状态能否预测乳腺癌新辅助化疗后的完全病理反应？
3. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer [J] . YangY.-F., LiaoY.-Y., LiL.-Q., Pathology Research and Practice . 2013,第12期

机译：乳腺癌新辅助化疗后ER，PR和HER2受体状态的变化
4. Immunohistochemistry applications in breast carcinoma: The Hypoxia Inducible Factor lα, Estrogen Receptor, Progesterone Receptor and HER2 expression before and after neoadjuvant chemotherapy [C] . Zuofeng Zhang, Yunai Liang, Chunhua Zhang, Technical Congress on Resources, Environment and Engineering . 2016

机译：免疫组织化学在乳腺癌中的应用：缺氧诱导因子Lα，雌激素受体，孕酮受体和Neoadjuvant化疗前后和Her2表达
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Oestrogen receptor status pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer [O] . A E Ring, I E Smith, S Ashley, 2004

机译：早期乳腺癌新辅助化疗患者的雌激素受体状态病理完全缓解和预后
7. O-29 Can ER/PR and HER2 receptor status predict complete pathological response after neo-adjuvant chemotherapy in patients with breast cancer? [O] . Sircar T., Brown H., Athwal R., 2010

机译：O-29 ER / PR和HER2受体状态能否预测乳腺癌新辅助化疗后的完全病理反应？

Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

著录项

相似文献

相关主题

期刊订阅